A history of late and very late stent thrombosis is not associated with increased activation of the contact system, a case control study

Table 2 Baseline biochemical characteristics for patients with a history of late or very late stent thrombosis (LST/VLST) and controls.

Characteristics	(V)LST group (n = 20)	PCI Control group (n = 32)	P
FXIIa (pM)*	70.0 (52.0-91.0)	67.5 (54.0-86.3)	0.95
FXII (%)*	99.0 (95.3-103.8)	99.0 (93.5-102.8)	0.79
FXIa-C1-inhibitor complex (%)*	0.17 (0.11-0.26)	0.21 (0.13-0.43)	0.25
FXIa-AT -complex (%)*	0.19 (0.15-0.27)	0.20 (0.15-0.28)	0.49
FXIIa-C1-inhibitor complex (%)*	0.11 (0.10-0.25)	0.13 (0.10-0.24)	0.80
Kallikrein-C1-inhibitor complex (%)*	0.10 (0.10-0.12)	0.10 (0.10-0.11)	0.93
Hs-CRP mg/L *	1.3 (1.0-3.1)	2.15 (1.0-3.8)	0.41
Se-creatinine (μmol/L)†	83.1 ± 18.0	85.9 ± 21.2	0.62
eGFR (ml/min)†	83 ± 19	79 ± 19	0.40
Hemoglobin g/dl†	14.0 ± 1.5	14.0 ± 1.4	0.94
Hematocrit %†	42.2 ± 4.1	41.8 ± 3.8	0.75
Thrombocytes (10⁹/L)†	251 ± 42	257 ± 79	0.78
Leucocytes (10⁹/L)†	6.6 ± 1.5	7.2 ± 2.4	0.25
Neutrophil count (10⁹/L)†	3.8 ± 1.0	4.4 ± 1.8	0.21
Basophil count (10⁹/L)†	0.01 ± 0.04	0.01 ± 0.03	0.95
Eosinophil count (10⁹/L)†	0.23 ± 0.21	0.21 ± 0.12	0.61
Total Cholesterol (mmol/L)†	3.80 ± 0.61	3.96 ± 0.92	0.66
LDL-Cholesterol (mmol/L)†	1.8 ± 0.6	1.8 ± 0.6	0.91
HDL-Cholesterol (mmol/L)†	1.33 ± 0.28	1.36 ± 0.75	0.91
Triglycerides (mmol/L)†	1.4 ± 0.8	1.7 ± 0.8	0.27
HbA1C % †	5.7 ± 0.8	5.8 ± 0.7	0.88

ISSN: 1477-9560